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ABSTRACT: The risk of developing hypersensitivity to alternative antibiotics is a concern for penicillin hypersensitive patients and 
healthcare providers. Herein we use piperacillin hypersensitivity as a model to explore the reactivity of drug-specific IgG against alter-
native β-lactam protein adducts. Mass spectrometry was used to show the drugs (amoxicillin, flucloxacillin, benzyl penicillin, aztre-
onam and piperacillin) bind to similar lysine residues on the protein carrier bovine serum albumin. However, the hapten-specific IgG 
antibodies found in piperacillin hypersensitive patient plasma did not bind to other β-lactam protein conjugates. These data outline 
the fine specificity of piperacillin-specific IgG antibodies that circulate in patients with hypersensitivity. 
-lactam antibiotics contain a -lactam ring structure that is 
critical for their anti-bacterial activity. These drugs are used 
either alone or in combination with -lactamase inhibitors 
which serve to conserve pharmacological activity and extend 
their spectrum. -lactam antibiotics have been implicated in a 
plethora of cutaneous hypersensitivity reactions that vary in 
severity and pathophysiology. Since all β-lactam antibiotics con-
tain the same reactive strained ring structure that is susceptible 
to nucleophilic attack by lysine residues on protein it is likely 
that similar neo-epitopes are generated in patients. Thus, inad-
vertent activation of the adaptive immune system in hypersensi-
tive patients due to cross-reactivity is an important clinical con-
cern.  
Piperacillin is a -lactam antibiotic commonly used to combat 
respiratory tract infections in patients with cystic fibrosis. Hy-
persensitivity reactions occur at a higher frequency in patients 
with cystic fibrosis when compared to the general population 
with an incidence of up to 30 % reported in some studies.1 
Thus, piperacillin hypersensitivity represents a relevant model 
to study the role of the adaptive immune system in the disease 
pathogenesis. We have recently found that T-cells from hyper-
sensitive patients are activated with piperacillin albumin ad-
ducts following protein processing by antigen presenting cells.2-4 
T-cell cross-reactivity with different drugs was not observed.5 In 
recent studies we have also detected piperacillin hapten-specific 
B-cells in the peripheral blood of hypersensitive patients.6 Stim-
ulation of the B-cells in vitro resulted in the secretion of IgG 
antibodies and the same antibodies were found to circulate in 
patient plasma.6 In the current study, structurally diverse β-
lactam bovine serum albumin (BSA) adducts were synthesized, 
characterized and used to explore whether IgG antibodies from 
patients react with different β-lactam structures (Figure 1). BSA 
was selected as a protein carrier since it contains a similar num-
ber of lysine residues to human serum albumin – the major 
target for piperacillin binding in patients – and the native pro-
tein displays limited reactivity against piperacillin-specific IgG.6  
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Figure 1. Structure of the β-lactam haptens bound to lysine residues on 
BSA. Red circles show the thiazolidine ring. 
Plasma from four hypersensitive patients was used to study IgG 
binding. Each patient developed maculopapular exanthema 
with or without drug-induced fever 3-7 days after initiation of 
piperacillin therapy. Blood samples were obtained with written 
consent and after approval by the Leeds East Ethics Committee. 
Peripheral blood mononuclear cells (PBMCs) were isolated 
using ficoll density centrifugation. The clinical diagnosis of 
piperacillin hypersensitivity was confirmed by in vitro assessment 
of T-cell proliferative responses using the lymphocyte transfor-
mation test. Lymphocytes from all four patients were stimulated 
to proliferate with piperacillin in a concentration-dependent 
manner (results not shown).   
 To prepare adducts, drugs (amoxicillin, flucloxacillin, benzyl 
penicillin, aztreonam and piperacillin) were incubated with BSA 
for 96h at a protein-drug molar ratio of 1:50. Ice-cold methanol 
was used to precipitate protein and the Bradford assay was used 
for protein quantification. Protein conjugates were purified 
using centrifugal filters wit he 3KDa cut-off. Western blotting 
using anti-penicillin or anti-flucloxacillin antibodies was per-
formed to confirm β-lactam-protein binding; visible bands at 
66kDa were observed for all drug protein adducts. Adducts 
were digested with trypsin prior to mass spectrometric analysis 
of site of drug modification. Samples were reconstituted in 2% 
acetonitrile / 0.1% formic acid (v/v) and delivered into a 
QTRAP 5500 hybrid quadrupole-linear ion trap mass spec-
trometer (Sciex) by automated in-line LC using an established 
method.3 MRM transitions specific for drug-modified peptides 
were selected as follows: the mass/charge ratio (m/z) values 
were calculated for all possible peptides with a missed cleavage 
at a lysine residue; to these were added the mass of the appro-
priate hapten; the parent ion masses were then paired with rele-
vant fragment masses. MRM transitions were acquired at unit 
resolution in both the Q1 and Q3 quadrupoles to maximize 
specificity. They were optimized for collision energy and colli-
sion cell exit potential, and the dwell time was 20ms. MRM 
survey scans were used to trigger enhanced product ion MS/MS 
scans of drug-modified peptides, with Q1 set to unit resolution, 
dynamic fill selected, and dynamic exclusion for 20s. Total ion 
counts were determined from a second aliquot of each sample 
analysed by conventional LC tandem MS and were used to 
normalize sample loading on column. MRM peak areas were 
determined by MultiQuant 1.2 software (Sciex). Epitope pro-
files were constructed by comparing the relative intensity of 
MRM peaks for each of the modified lysine residues within a 
sample and normalization of those signals across samples. 
Epitope profiles showed that a similar panel of lysine residues 
on BSA was modified with amoxicillin, benzyl penicillin, pipe-
racillin and flucloxacillin (Figure 2). Lysine residues on all 4 
conjugates were haptenated at positions 4, 12, 211, 431 and 
524. Three of the drugs modified lysine residues at positions 
132, 136 and 523. Amoxicillin and benzyl penicillin alone 
modified lysine 20, 473 and 537, while lysine 535 was only 
modified with flucloxacillin. A more restricted binding profile 
was observed with aztreonam; modifications were only detected 
on lysine residues at positions 136, 211 and 524.      
ELISA was used for the detection of anti-drug IgG antibody 
levels in hypersensitive patient plasma. Plates were coated over-
night at 4 oC with a 20 µg/ml solution of drug BSA adducts. 
Piperacillin (1 mM) was added to certain wells for 16 h, prior to 
the addition of BSA adducts, for hapten inhibition. Following 
washing and blocking, a 1/10 dilution of plasma from the pa-
tients was added. Goat anti-human IgG, a horseradish peroxi-
dase-labelled rabbit anti-goat IgG and TMB substrate were used 
to visualize bound anti-piperacillin IgG. Absorbance values were 
read at 490nm using an automated plate reader (Dynatech 
MR600, Hendersonville, TN, USA).  
Substantial piperacillin IgG binding to piperacillin-modified-
BSA was observed with plasma form all four patients (Figure 3). 
Antibody binding was reduced by greater than 85% when the 
antibody was pre-incubated with soluble piperacillin in hapten 
inhibition experiments. Antibody binding was not observed 
when the piperacillin-BSA adduct was replaced with amoxicil-
lin, aztreonam, or benzyl penicillin-BSA adducts, while very low 
levels of binding was detected with the flucloxacillin-BSA ad-
duct (Figure 3).    
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       Figure 2. Epitope profile for piperacillin, amoxicillin, aztreonam, 
flucloxacillin and benzyl penicillin BSA adducts. Adducts were gener-
ated by culturing BSA with the drugs at a 1:50 ratio for 96 h. Proteins 
were denatured, digested with trypsin and desalted prior to characteri-
zation by mass spectrometry.  
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Figure 3. Detection of piperacillin IgG binding to different β-lactam 
BSA adducts using ELISA. (A) Results using plasma from the patient 
with highest levels of piperacillin-specific IgG is shown to illustrate 
control values and the effect of hapten inhibition. Data shows 
mean±SD hapten inhabitable antibody binding to the different BSA 
adducts.  (B) Mean data showing hapten-inhabitable IgG values ob-
tained with plasma from 4 piperacillin hypersensitive patients. Error 
bars have been omitted for clarity. Data was analysed with the Students 
T-test to compare differences between means.    
Previous studies with PBMC and cloned T-cells from piperacil-
lin hypersensitive patients revealed low levels of cross 
reactivity.4, 5 Our recent discovery of piperacillin-specific IgG in 
hypersensitive patient plasma6 prompted us to investigate 
whether piperacillin-specific IgG bound to different β-lactam 
protein conjugates. Mass spectrometry revealed that the differ-
ent drugs bound to a similar panel of lysine residues on the 
protein carrier BSA, albeit at different levels. However, the ab-
sence of piperacillin-specific IgG binding to amoxicillin, aztre-
onam and benzyl penicillin adducts and the low levels of bind-
ing seen with the flucloxacillin adduct shows that the humoral 
immune response induced in hypersensitive patients is also 
highly structurally specific. IgG antibodies must interact with 
the penicilloyl structure as well as the side chain of piperacillin 
to confer such specificity.   
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